CITADEL ADVISORS LLC 13D and 13G filings for Design Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 4:58 pm Sale |
2023-12-31 | 13G | Design Therapeutics, Inc. DSGN |
CITADEL ADVISORS LLC | 1,834,854 3.300% |
-1,036,413 (-36.10%) |
Filing |
| 2023-04-03 4:55 pm Purchase |
2023-03-23 | 13G | Design Therapeutics, Inc. DSGN |
CITADEL ADVISORS LLC | 2,871,267 5.100% |
203,037 (+7.61%) |
Filing |
| 2023-02-14 08:14 am Sale |
2022-12-31 | 13G | Design Therapeutics, Inc. DSGN |
CITADEL ADVISORS LLC | 2,668,230 4.800% |
-40,017 (-1.48%) |
Filing |
| 2022-12-22 4:01 pm Purchase |
2022-12-12 | 13G | Design Therapeutics, Inc. DSGN |
CITADEL ADVISORS LLC | 2,708,247 4.800% |
2,708,247 (New Position) |
Filing |